Insulin Resistance - Pipeline Review, H2 2018

  • ID: 4592421
  • Drug Pipelines
  • 46 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Caelus Health
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • NorthSea Therapeutics BV
  • Pfizer Inc
  • MORE
Insulin Resistance - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Pipeline Review, H2 2018, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body’s own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

Report Highlights:

This latest pipeline guide Insulin Resistance - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Caelus Health
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • NorthSea Therapeutics BV
  • Pfizer Inc
  • MORE
Introduction

Report Coverage

Insulin Resistance - Overview

Insulin Resistance - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Insulin Resistance - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insulin Resistance - Companies Involved in Therapeutics Development

Amgen Inc

BioElectron Technology Corp

Caelus Health

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

NorthSea Therapeutics BV

Pfizer Inc

Sanofi

Insulin Resistance - Drug Profiles

ATA-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BioE-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDN-1163 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

englerin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FC-98 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Target hOGG1 for Insulin Resistance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7992 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target AGTR1 and PPAR Gamma for Hypertension and Insulin Resistance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Inmmunology, Metabolic Disorders and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYM-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-25659 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Insulin Resistance - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Insulin Resistance, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Insulin Resistance - Pipeline by Amgen Inc, H2 2018

Insulin Resistance - Pipeline by BioElectron Technology Corp, H2 2018

Insulin Resistance - Pipeline by Caelus Health, H2 2018

Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H2 2018

Insulin Resistance - Pipeline by NorthSea Therapeutics BV, H2 2018

Insulin Resistance - Pipeline by Pfizer Inc, H2 2018

Insulin Resistance - Pipeline by Sanofi, H2 2018

Insulin Resistance - Dormant Projects, H2 2018

Insulin Resistance - Dormant Projects, H2 2018 (Contd..1), H2 2018

List of Figures

Number of Products under Development for Insulin Resistance, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • BioElectron Technology Corp
  • Caelus Health
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • NorthSea Therapeutics BV
  • Pfizer Inc
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll